[1] 胡晓丽, 赵宏伟, 吴晓岩, 等.乙型肝炎病毒感染的流行现状. 临床肝胆病杂志, 2012,28:413-416.
[2] Yang J, Xu G, Zheng Y, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases.Chromatography B,2004,813:59-65.
[3] Ippolito JE, Xu J, Jain S, et al. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.Proc Natl Acad Sci USA, 2005,102:9901-9906.
[4] Nicholson JK, Lindon JC, Holmes E, et al. 'Metabonomics': understanding the metabolic responses of living system s to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 1999,29:1181-1189.
[5] Jenkins H, Hardy N, Beckmann M, et al. A proposed framework for the description of plant metabolomics experiments and their results. Nat Biotechnol, 2004,22:1601-1606.
[6] German JB, Bauman DE, Burrin DG, et al. Metabolomics in the opening decade of the 21st century: building the roads to individualized health. J Nutr, 2004,134:2729-2732.
[7] Fiehn O. Metabolomics the link between genotypes and phenotypes. Plant Mol Biol, 2002,48:155-171.
[8] 侯玉洁, 祝文君, 陈长功, 等. 基于气相色谱质谱联用技术的乙型肝炎血清代谢标志物的探究. 色谱, 2015,4:383-388.
[9] Zhang A, Sun H, Han Y, et al. Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system. PLoS One, 2013,8:DOI:10.1371/journal.pone.0064381.
[10] Gao R, Cheng J, Fan C, et al. Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma. SciRep, 2015,5:DOI:10.1038/srep 18175.
[11] Shao X, Niu J. A metabonomics study of chronic hepatitis B in different stages. Gastroenterol Hepatol, 2013, 28:644-644.
[12] Qi S, Tu Z, Ouyang X, et al. Comparison of the metabolic profiling of hepatitis B virus-infected cirrhosis and alcoholic cirrhosis patients by using 1H NMR-based metabonomics. Hepatol Res, 2012,42:677-685.
[13] McPhail MJ, Shawcross DL, Lewis MR, et al. Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. Hepatology, 2016,64:1058-1067.
[14] Dabos KJ, Parkinson JA, Sadler IH,et al. 1H nuclear magnetic resonance spectroscopy-based metabonomic study in patients with cirrhosis and hepatic encephalopathy. World J Hepatol, 2015,7:1701-1707.
[15] Tsai T, Song E, Zhu R, et al. LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics, 2015,15:2369-2381.
[16] Liu S, Zhang RL, Kang H, et al. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol, 2013,19:3423-3432.
[17] Tan Y, Yin P, Tang L, et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics,2012, 11:DOI:10.1.74/mcp. M111.010694.11.
[18] Chen F, Xue J, Zhou L, et al. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem,2011,401: 1899-1904.
[19] Wang B, Chen D, Chen Y, et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res, 2012,11:1217-1227.
[20] Lu YH, Huang C, Gao L, et al. Identification of serum biomarkers associated with hepatitis B virus-related hepatocellular carcinoma and liver cirrhosis using mass-spectrometry-based metabolomics. Metabolomics,2015,11:1526-1538.
[21] Li H, Zhu W, Zhang L, et al. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. Scientific Reports, 2015,5:DOI:10.1038/srep08421.
[22] 中华医学会感染病学分会肝衰竭与人工肝学组. 肝衰竭诊治指南(2012年版).临床传染病学杂志,2012,5:321-327.
[23] Yu K, Sheng G, Sheng J, et al. A metabonomic investigation on the biochemical perturbation in liver failure patients caused by hepatitis B virus. J Proteome Res, 2007,6:2413-2419.
[24] Amathieu R, Triba MN, Nahon P, et al. Serum 1H-NMR metabolomic fingerprints of acute-on-chronic liver failure in intensive care unit patients with alcoholic cirrhosis. PLoS One, 2014,9:DOI:10.1371/journal.pone.0089230.
[25] Ott M, Cantz T, Schneider A, et al. Diagnostik and behandlung des akuten leberversagens. Der Internist, 2014,55:1288-1295.
[26] Chen E, Zeng F, Zhou L, et al. Early warning and clinical outcome prediction of acute-on- chronic hepatitis B liver failure. World J Gastroenterol, 2015,21:11964-11973.
[27] Mao Y, Huang X, Yu K, et al. Metabonomic analysis of hepatitis B virus-induced liver failure: identification of potential diagnostic biomarkers by fuzzy support vector machine. J Zhejiang Univ Sci B, 2008,9:474-481.
[28] Zhang L, Jia X, Peng X, et al. Development and validation of a liquid chromatography-mass spectrometry metabonomic platform in human plasma of liver failure caused by hepatitis B virus. Acta Biochimica et Biophysica Sinica, 2010,42:688-698.
[29] Nie CY, Han T, Zhang L, et al. Cross-sectional and dynamic change of serum metabolite profiling for hepatitis B-related acute-on-chronic liver failure by UPLC/MS. Journal of Viral Hepatitis, 2014,21:53-63.
[30] Amathieu R, Nahon P, Triba M, et al. Metabolomic approach by 1H NMR spectroscopy of serum for the assessment of chronic liver failure in patients with cirrhosis.J Proteome Res, 2011,10:3239-3245.
[31] Longo N, Ardon O, Vanzo R, et al. Disorders of creatine transport and metabolism. Am J Med Genet C: Seminars in Medical Genetics, 2011,157:72-78.
[32] 许彬, 王海龙, 魏开华, 等. 代谢组学分析技术及其在几类重大疾病研究中的应用.分析测试学报, 2006:128-132.
[33] 汪茂荣. 《国际肝性脑病和氮质代谢共识》解读:肝硬化患者肝性脑病的营养管理.实用肝脏病杂志, 2013,4:303-305.
[34] Holecek M. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives. Metab Brain Dis, 2014,29:9-17.
[35] 齐素文, 戴勇, 欧阳昕, 等. 轻微肝性脑病患者血清中代谢物组的研究. 第三军医大学学报, 2011,23:2503-2507. |
